By Regenerative Medicine China · Published and sources checked · Patient information. Individual treatment and study eligibility require the responsible clinical team’s assessment.
What should a family prepare before traveling to Shanghai for pancreatic cancer trial screening?
First confirm the named study and site's current status. Ask whether the research team can review records remotely, then send the requested pathology, molecular reports, treatment history, scans, medicines and recent clinical information through its approved channel. Obtain a written preliminary response before making travel commitments; prescreening does not guarantee enrollment.
Verify the study before assembling a large file
Record the registry identifier, treatment name, site and date of the latest update. For example, Shanghai IX001 study NCT06487377 is withdrawn: its September 2, 2026 update reports no patients dosed. NCT04146298 concerns KRAS G12V/HLA-A*11:01, a different pairing from G12D/HLA-C*08:02. The G12D master study NCT06218914 currently lists United States sites.
Ask the named site to confirm whether it is reviewing new inquiries for the relevant arm. A registry status, a published paper and an appointment offer answer different questions. None alone confirms that this patient has a study place.
Start with a short clinical summary
Ask whether remote prescreening is available and what the team requires. A useful cover sheet gives the diagnosis, current disease sites, treatment sequence, dates of the most recent treatment and scan, and the treating oncologist's contact details with permission. Include the precise molecular result when relevant.
Label missing information as pending instead of guessing. The initial goal is to help the reviewer decide which records to request and whether further assessment makes sense. NCI describes trial matching as a comparison of diagnosis, previous treatment and current health against protocol requirements. NCI trial-search guidance.
Prepare pathology, imaging and laboratory records
Have the full pathology report and molecular-testing reports available. Ask whether slides, tissue blocks or another sample are required, and obtain specific transfer instructions before sending physical material. For imaging, ask whether the reviewer needs the original DICOM files alongside the radiology report. Phone photographs of selected scan images may leave the reviewer unable to assess the complete examination.
Organize requested laboratory results by date, with units and reference ranges intact. Ask how recent results must be and which tests need repeating. NCI's own early-phase clinic describes review of records, scans and pathology before a screening visit, with clinical examinations and laboratory assessment when needed. This illustrates a process; it does not set Shanghai requirements. NCI: What to Expect.
Describe current fitness and medicines accurately
Include an up-to-date medicine list, doses and the last administration dates of cancer treatments. Mention steroids, blood thinners, supplements and other prescribed medicines. Ask the treating team to summarize daily functioning, recent admissions, infections, treatment side effects and any biliary stent or drainage procedure.
These details give the reviewer a current clinical picture. Individual protocols may assess blood counts, liver and kidney function, performance status and additional conditions; the requirements vary. NCI explains eligibility criteria. Any treatment pause, washout period or medicine adjustment requires the responsible clinicians' instructions. Do not make changes to fit a presumed rule.
Request a written preliminary answer
Ask the reviewing team to identify the study and arm, review date, records considered and unresolved requirements. The reply should specify the next step: more documents, formal screening, waiting for capacity or another option.
Ask who made the clinical assessment and who will coordinate with the treating oncologist. Keep the original response. If an intermediary relays a conclusion, request the study-team message. Prescreening is preliminary; final eligibility may require examinations, repeat tests and the study's consent process.
Use an agreed channel for sensitive records
Before uploading anything, confirm the recipient's role and the institution's accepted transfer method. Ask which identifiers are necessary, who can access the file, whether translation is needed and how corrections or deletion requests are handled. Obtain the patient's permission for family members or coordinators to share records.
Keep an index of what was sent and when. Scan files can contain identifying information as well as images, so ask for instructions before sharing them through public links. Send only the requested material and preserve the unaltered originals for clinical review.
Resolve practical commitments before travel
Request an itemized explanation of screening costs, repeat testing, translation, accommodation, caregiver needs and follow-up visits. Ask what happens financially if screening fails or a study place becomes unavailable. Trial participation does not automatically make every associated expense free. NCI distinguishes research costs from ordinary patient-care costs; local arrangements need their own written confirmation. NCI's explanation of trial costs.
Ask which parts of assessment can be completed locally and how long an initial visit may take. Keep current care coordinated with the treating team while the research inquiry proceeds.
Prepare for your review
- Current study identifier, arm and named reviewing team
- Requested records, dated medicine list and clinical summary
- Confirmed secure transfer and patient permission
- Written preliminary outcome, remaining tests and next contact
- Screening costs, travel needs and follow-up responsibilities
Common questions
Can remote prescreening guarantee enrollment?
No. It can identify a possible match or missing information. Final screening and the research team's decision are still required.
Must every patient obtain new HLA testing?
Ask the team running the specific study. HLA testing is relevant to certain therapies, including HLA-restricted TCR-T, but it is not a universal requirement for all pancreatic cancer trials.
Should we book travel when an old listing says recruiting?
First request current confirmation from the named site and a written explanation of the next step. The withdrawn IX001 record shows why older listings can be misleading.
Should treatment stop while records are reviewed?
Do not change prescribed treatment on the basis of a website or informal prescreening message. Timing decisions belong with the treating and research clinicians.
Sources and evidence boundaries
- ClinicalTrials.gov: IX001, NCT06487377 (withdrawn)
- ClinicalTrials.gov: KRAS G12V TCR-T, NCT04146298
- ClinicalTrials.gov: KRAS TCR-T master protocol, NCT06218914
- NCI: Steps to Find a Clinical Trial
- NCI Developmental Therapeutics Clinic: What to Expect
- NCI: How Do Clinical Trials Work?
- NCI: Who Pays for Clinical Trials?
Registry status and local access can change. A public listing, molecular match or source citation is not a hospital partnership, a reserved place or confirmation of eligibility. Published research and overseas approvals should be interpreted in their stated setting. This guide does not present an RMC patient outcome.